GB201016742D0 - Clostridium difficile antigens - Google Patents

Clostridium difficile antigens

Info

Publication number
GB201016742D0
GB201016742D0 GBGB1016742.7A GB201016742A GB201016742D0 GB 201016742 D0 GB201016742 D0 GB 201016742D0 GB 201016742 A GB201016742 A GB 201016742A GB 201016742 D0 GB201016742 D0 GB 201016742D0
Authority
GB
United Kingdom
Prior art keywords
clostridium difficile
difficile antigens
antigens
clostridium
difficile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1016742.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Public Health England
Original Assignee
Health Protection Agency
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Protection Agency filed Critical Health Protection Agency
Priority to GBGB1016742.7A priority Critical patent/GB201016742D0/en
Publication of GB201016742D0 publication Critical patent/GB201016742D0/en
Priority to PCT/GB2011/051910 priority patent/WO2012046061A2/en
Priority to SG2013021506A priority patent/SG189058A1/en
Priority to EP11769913.2A priority patent/EP2625193B1/en
Priority to CN201180047913.3A priority patent/CN103237807B/zh
Priority to AU2011311321A priority patent/AU2011311321B2/en
Priority to JP2013532271A priority patent/JP6377907B2/ja
Priority to US13/878,150 priority patent/US10369206B2/en
Priority to BR112013008407A priority patent/BR112013008407A2/pt
Priority to CA2812731A priority patent/CA2812731C/en
Priority to US16/511,503 priority patent/US20190328859A1/en
Priority to US17/224,404 priority patent/US20210369830A1/en
Priority to US17/821,730 priority patent/US12491239B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB1016742.7A 2010-10-05 2010-10-05 Clostridium difficile antigens Ceased GB201016742D0 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
GBGB1016742.7A GB201016742D0 (en) 2010-10-05 2010-10-05 Clostridium difficile antigens
CA2812731A CA2812731C (en) 2010-10-05 2011-10-05 Clostridium difficile antigens
JP2013532271A JP6377907B2 (ja) 2010-10-05 2011-10-05 クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ）抗原
SG2013021506A SG189058A1 (en) 2010-10-05 2011-10-05 Clostridium difficile antigens
EP11769913.2A EP2625193B1 (en) 2010-10-05 2011-10-05 Clostridium difficile antigens
CN201180047913.3A CN103237807B (zh) 2010-10-05 2011-10-05 艰难梭菌抗原
AU2011311321A AU2011311321B2 (en) 2010-10-05 2011-10-05 Clostridium difficile antigens
PCT/GB2011/051910 WO2012046061A2 (en) 2010-10-05 2011-10-05 Clostridium difficile antigens
US13/878,150 US10369206B2 (en) 2010-10-05 2011-10-05 Clostridium difficile antigens
BR112013008407A BR112013008407A2 (pt) 2010-10-05 2011-10-05 antígenos de clostridium difficile
US16/511,503 US20190328859A1 (en) 2010-10-05 2019-07-15 Clostridium difficile antigens
US17/224,404 US20210369830A1 (en) 2010-10-05 2021-04-07 Clostridium difficile antigens
US17/821,730 US12491239B2 (en) 2010-10-05 2022-08-23 Clostridium difficile antigens

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1016742.7A GB201016742D0 (en) 2010-10-05 2010-10-05 Clostridium difficile antigens

Publications (1)

Publication Number Publication Date
GB201016742D0 true GB201016742D0 (en) 2010-11-17

Family

ID=43243528

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1016742.7A Ceased GB201016742D0 (en) 2010-10-05 2010-10-05 Clostridium difficile antigens

Country Status (10)

Country Link
US (4) US10369206B2 (enExample)
EP (1) EP2625193B1 (enExample)
JP (1) JP6377907B2 (enExample)
CN (1) CN103237807B (enExample)
AU (1) AU2011311321B2 (enExample)
BR (1) BR112013008407A2 (enExample)
CA (1) CA2812731C (enExample)
GB (1) GB201016742D0 (enExample)
SG (1) SG189058A1 (enExample)
WO (1) WO2012046061A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201016742D0 (en) 2010-10-05 2010-11-17 Health Prot Agency Clostridium difficile antigens
CN103619871B (zh) 2011-04-22 2016-12-14 惠氏有限责任公司 涉及突变体难辨梭菌毒素的组合物及其方法
CN107098977A (zh) * 2011-05-27 2017-08-29 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
KR20140101835A (ko) * 2011-12-08 2014-08-20 노파르티스 아게 클로스트리듐 디피실레 톡신-기반 백신
GB201206070D0 (en) * 2012-04-04 2012-05-16 Health Prot Agency Clostridium difficile antigens
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
WO2014085749A2 (en) * 2012-11-28 2014-06-05 Cnj Holdings, Inc. Antibodies against clostridium difficile
CN103865938B (zh) * 2012-12-16 2016-10-05 山东国际生物科技园发展有限公司 艰难梭菌外毒素a羧基端序列密码子优化基因片段、表达载体构建方法及其表达蛋白的应用
US9493518B2 (en) 2013-03-14 2016-11-15 National Health Research Institutes Compositions and methods for treating clostridium difficile-associated diseases
WO2014176276A1 (en) * 2013-04-22 2014-10-30 Board Of Regents Of The University Of Oklahoma Clostridium difficile vaccine and methods of use
GB201309421D0 (en) * 2013-05-24 2013-07-10 Imp Innovations Ltd Polypeptides
CN103772509B (zh) * 2014-01-20 2017-01-11 山东国际生物科技园发展有限公司 一种艰难梭菌毒素a/b的融合蛋白及其编码基因与应用
EP3344276B1 (en) * 2015-09-03 2020-04-22 The Board of Regents of the University of Oklahoma Peptide inhibitors of clostridium difficile tcdb toxin
WO2019143552A1 (en) * 2018-01-16 2019-07-25 Children's Medical Center Corporation Compositions and methods for inhibiting wnt signaling
CN113195521B (zh) * 2018-12-19 2023-05-12 清华大学 Mtu ΔI-CM内含肽变体和其应用
WO2021255690A2 (en) 2020-06-19 2021-12-23 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
CN116981621B (zh) * 2021-02-09 2024-07-02 杰欧比飞行有限公司 飞行器推进单元
CN113717263B (zh) * 2021-08-04 2022-06-07 河北医科大学第二医院 一种艰难梭菌特异性抗原肽
CN115093470B (zh) * 2022-06-30 2023-03-24 广州市乾相生物科技有限公司 内含肽Mtu RecA突变体及其在生产谷胱甘肽GSH中的应用
CN120484111B (zh) * 2025-05-14 2025-10-28 广州海绿生物技术有限公司 一种包含益生菌的组合物及其在治疗肠胃疾病中的用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
AU709586B2 (en) * 1994-10-24 1999-09-02 Ophidian Pharmaceuticals, Inc. Vaccine and antitoxin for treatment and prevention of C. difficile disease
US5919463A (en) 1995-07-07 1999-07-06 Oravax, Inc. Clostridium difficle toxins as mucosal adjuvants
WO1998059053A1 (en) 1997-06-20 1998-12-30 Queen Mary & Westfield College Immonogenic fragments of toxin a of clostridium difficile
JP2002542169A (ja) 1999-04-09 2002-12-10 テクラブ， インコーポレイテッド Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅに対する、組換え毒素Ａ／毒素Ｂワクチン
WO2002062379A2 (en) 2001-02-09 2002-08-15 The Provost, Fellows And Scholars Of The College Of The Holy And Unidivided Trinity Of Queen Elizabeth Clostridium difficile vaccine
NZ548821A (en) * 2004-02-06 2009-12-24 Univ Massachusetts Antibodies against clostridium difficile toxins and uses thereof
WO2007146139A2 (en) 2006-06-08 2007-12-21 Cornell Research Foundation, Inc. Codon-optimized dna molecules encoding the receptor binding domains of clostridium difficile toxins a and b
CA2733425A1 (en) * 2008-08-06 2010-02-11 Emergent Product Development Uk Limited Vaccines against clostridium difficile and methods of use
GB0921288D0 (en) 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
GB201016742D0 (en) 2010-10-05 2010-11-17 Health Prot Agency Clostridium difficile antigens
CN103619871B (zh) * 2011-04-22 2016-12-14 惠氏有限责任公司 涉及突变体难辨梭菌毒素的组合物及其方法

Also Published As

Publication number Publication date
CN103237807B (zh) 2016-10-26
JP2014502253A (ja) 2014-01-30
EP2625193A2 (en) 2013-08-14
WO2012046061A2 (en) 2012-04-12
AU2011311321B2 (en) 2016-05-19
US12491239B2 (en) 2025-12-09
BR112013008407A2 (pt) 2016-06-21
CA2812731A1 (en) 2012-04-12
AU2011311321A1 (en) 2013-04-11
SG189058A1 (en) 2013-05-31
CN103237807A (zh) 2013-08-07
US10369206B2 (en) 2019-08-06
US20190328859A1 (en) 2019-10-31
JP6377907B2 (ja) 2018-08-22
CA2812731C (en) 2021-07-06
US20130266583A1 (en) 2013-10-10
US20210369830A1 (en) 2021-12-02
US20230165949A1 (en) 2023-06-01
WO2012046061A3 (en) 2012-12-20
EP2625193B1 (en) 2018-04-04

Similar Documents

Publication Publication Date Title
GB201016742D0 (en) Clostridium difficile antigens
PT3564357T (pt) Bacterioterapia para colite por clostridium difficile
SG11201400916XA (en) Clostridium difficile antibodies
ZA201209004B (en) Anti-fgfr2 antibodies
GB201000467D0 (en) Antibodies
HUE040213T2 (hu) Anti-TIM antitest
LT3342786T (lt) Anti-dll3 antikūnai
IL221371A0 (en) Anti-lrp6 antibodies
GB201103955D0 (en) Antibodies
GB201112056D0 (en) Antibodies
PL2616489T3 (pl) Przeciwciało anty-huTNFR1
IL231304A0 (en) Anti-alphabetatisiar antibody
ZA201302459B (en) Antibodies
IL225667A0 (en) A new antigen
GB201020738D0 (en) Antibodies
PL2603528T3 (pl) Przeciwciała Fab-glikozylowane
IL232957A0 (en) A composition based on clostridium difficile toxin
GB201002238D0 (en) Antibodies
SG11201406301TA (en) Clostridium difficile antigens
EP2925362A4 (en) ANTIBODIES DIRECTED AGAINST CLOSTRIDIUM DIFFICILE
IL237172A0 (en) פוליפפטידים של clostridium difficile כתרכיבים
EP2714074A4 (en) ANTIBODIES AGAINST EMR1
GB201007957D0 (en) Antibody
IL231661A0 (en) Clostridium difficile antibodies
GB201121149D0 (en) Clostridium difficile toxin-based vaccine

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)